about
Dexamethasone administration attenuates the inhibitory effect of lipopolysaccharide on IGF-I and IGF-binding protein-3 in adult ratsαMSH blunts endotoxin-induced MuRF1 and atrogin-1 upregulation in skeletal muscle by modulating NF-κB and Akt/FoxO1 pathwayD-TRP(8)-γMSH Prevents the Effects of Endotoxin in Rat Skeletal Muscle Cells through TNFα/NF-KB Signalling Pathway.The melanocortin receptor type 3 agonist d-Trp(8)-γMSH decreases inflammation and muscle wasting in arthritic rats.Eicosapentaenoic acid attenuates arthritis-induced muscle wasting acting on atrogin-1 and on myogenic regulatory factors.Inactivation of Kupffer cells by gadolinium administration prevents lipopolysaccharide-induced decrease in liver insulin-like growth factor-I and IGF-binding protein-3 gene expression.GH administration and renal IGF-I system in arthritic rats.NO plays a role in LPS-induced decreases in circulating IGF-I and IGFBP-3 and their gene expression in the liver.The inhibition of inducible nitric oxide synthase reverts arthritic-induced decrease in pituitary growth hormone mRNA but not in liver insulin-like growth factor I mRNA expression.Effect of inducible nitric oxide synthase inhibition by aminoguanidine on insulin-like growth factor binding protein-3 in adjuvant-induced arthritic rats.Naltrexone does not reverse the inhibitory effect of chronic restraint on gonadotropin secretion in the intact male rat.Systemic IGF-I administration attenuates the inhibitory effect of chronic arthritis on gastrocnemius mass and decreases atrogin-1 and IGFBP-3.Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats.Endotoxin administration increases hypothalamic somatostatin mRNA through nitric oxide release.Cyclooxygenase-2 inhibition reverts the decrease in adiponectin levels and attenuates the loss of white adipose tissue during chronic inflammation.Cyclooxygenase-2 [corrected] activation by endotoxin mediates the decrease in IGF1, but not in IGFBP3, [corrected] gene expression in the liver.Adipose tissue loss in adjuvant arthritis is associated with a decrease in lipogenesis, but not with an increase in lipolysis.GH-releasing peptide-2 administration prevents liver inflammatory response in endotoxemia.Endotoxin at low doses stimulates pituitary GH whereas it decreases IGF-I and IGF-binding protein-3 in rats.Systemic α-melanocyte-stimulating hormone administration decreases arthritis-induced anorexia and muscle wasting.Experimental arthritis inhibits the insulin-like growth factor-I axis and induces muscle wasting through cyclooxygenase-2 activation.Effects of endotoxin lipopolysaccharide administration on the somatotropic axis.Effects of catecholamine synthesis inhibitors and adrenergic receptor antagonists on restraint-induced LH release.The decrease in hepatic IGF-I gene expression in arthritic rats is not associated with modifications in hepatic GH receptor mRNA.Tumour necrosis factor blockade did not prevent the increase of muscular muscle RING finger-1 and muscle atrophy F-box in arthritic rats.Nitric oxide production by hepatocytes contributes to the inhibitory effect of endotoxin on insulin-like growth factor I gene expression.IGF-I system, atrogenes and myogenic regulatory factors in arthritis induced muscle wasting.Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1Fenofibrate, a PPARα agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophyAnti-tumor necrosis factor agent PEG-sTNFRI improves the growth hormone/insulin-like growth factor-I system in adjuvant-induced arthritic ratsGhrelin receptor agonist GHRP-2 prevents arthritis-induced increase in E3 ubiquitin-ligating enzymes MuRF1 and MAFbx gene expression in skeletal muscleEndotoxin decreases serum IGFBP-3 and liver IGFBP-3 mRNA: comparison between Lewis and Wistar ratsArthritis-induced increase in serum levels of IGF-binding protein-3 in rats is secondary to the decrease in its proteolytic activityIGF-I and IGF-I-binding proteins in rats with adjuvant-induced arthritis given recombinant human growth hormoneChronic inflammation inhibits GH secretion and alters the serum insulin-like growth factor system in ratsThe effect of cyclosporine administration on growth hormone release and serum concentrations of insulin-like growth factor-I in male ratsShort and long restraint differentially affect humoral and cellular immune functionsRestraint-Induced Changes in Serum Luteinizing Hormone, Prolactin, Growth Hormone and Corticosterone Levels in Rats: Effect of Superior Cervical Ganglionectomy
P50
Q28854319-AF9ED70C-A035-49EA-BA08-A6D67F3DD54EQ34247135-54267959-B472-47AC-B855-DC96CBDD6211Q36017471-FBD23036-7A0C-468C-8E2B-DD258FB42E5AQ36706589-456CB423-69F8-48DE-AE79-3D0614DA2327Q43278882-A3F75484-9507-4B4D-A233-322B6FCF0A73Q43517995-8A6FF360-201A-44E9-9E88-372115EC8952Q44006824-5B418FB1-675C-4934-86DB-E2D2C4FE0A18Q44586422-A32E956D-3773-4A86-A5E1-116D9E8CD0AFQ44667798-3A0343D5-13D0-413A-B8E9-9BB8173C3F1CQ44671951-BAA139D4-7BE7-4DCE-B662-8D51FC562890Q44688118-A92B7556-86B9-4412-8FEF-D691EE19CBCAQ44803921-DA896D3B-70D0-4801-98DD-E7856A6C2F4AQ45126768-00037DD4-521C-4EBF-BA32-5AFDBC0DD5E3Q45151341-568D1031-F3A2-4BAB-9A2C-85330A6F74DDQ46087028-32B6C66F-CBB7-4344-9B8D-D750A036FB10Q46585158-51AAEC83-CF25-4026-A706-03AD54936412Q46677464-482CC6B2-5CCD-4357-BD91-718BBFB02F48Q46911942-811AF604-6AEE-4225-82DD-BCE891C545AAQ47582973-963577DB-8A5F-4259-BFC9-722733569694Q48117321-A107859A-9325-45CD-94FF-4AC1E56F64A1Q48281187-7D39A43E-B1D4-46E8-A3A6-3A184B79A573Q48363264-EB70B849-3076-4D32-BFDF-F2B44729AFF0Q49172529-D6636FBF-CFAE-4727-A191-52E12EA897F2Q54139890-DE55B35C-8103-4F99-AE85-55842E96E4BDQ54574421-A5A74594-2A48-4FFC-B161-A897136B8CB2Q54579297-AD21EEF5-0A2D-4C34-8FD0-57C42489A4F9Q54741209-C31ABB10-18C9-4471-B3E1-05FE4740D465Q59708802-19EBDACF-3843-4838-A860-B24519688CA8Q59708806-7E2DCD34-66B2-437F-899C-28F15A3FAB81Q59708847-43BA9266-801E-4B3C-AA62-10F71316EB2BQ59708869-5B2A9280-DC08-4422-A367-39B6BBAC7375Q59708876-A0E1D665-6AAE-40F0-BE71-6C8CC9F279D0Q59708884-8705A4ED-7044-453E-BA94-24F7C85B596CQ59708916-8D741217-CB34-467D-B80C-F86AF5F556D8Q59708920-BD955FCC-EF12-4B1B-8876-2E3C346C65FEQ59708925-29AD6C67-F06E-40BE-9995-58480A87E4B9Q59708933-B0432A28-636C-4AFB-B801-555DD4B20750Q59708940-13952858-8F82-411F-9868-88FA2D9E2FF3
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ana Isabel Martín
@ast
Ana Isabel Martín
@en
Ana Isabel Martín
@es
Ana Isabel Martín
@nl
Ana Isabel Martín
@sl
type
label
Ana Isabel Martín
@ast
Ana Isabel Martín
@en
Ana Isabel Martín
@es
Ana Isabel Martín
@nl
Ana Isabel Martín
@sl
prefLabel
Ana Isabel Martín
@ast
Ana Isabel Martín
@en
Ana Isabel Martín
@es
Ana Isabel Martín
@nl
Ana Isabel Martín
@sl
P1053
K-5301-2014
P106
P21
P31
P3829
P496
0000-0002-4445-590X